<div id="readability-page-1"><p>U.S. Capital Wealth Advisors LLC boosted its position in shares of  Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 48.2% in the 3rd quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 94,165 shares of the biotechnology company's stock after buying an additional 30,619 shares during the quarter. U.S. Capital Wealth Advisors LLC owned 0.08% of Viking Therapeutics worth $2,475,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p><div><p><span></span><span>Get <strong>Viking Therapeutics</strong> alerts:</span></p></div><ul><li>Viking Therapeutics: High Risk, High Reward Play</li></ul><p>A number of other hedge funds have also bought and sold shares of the company. Allworth Financial LP boosted its stake in shares of  Viking Therapeutics by 58.4% during the 2nd quarter. Allworth Financial LP now owns 955 shares of the biotechnology company's stock worth $25,000 after purchasing an additional 352 shares during the period.  Glass Jacobson Investment Advisors llc purchased a new position in shares of  Viking Therapeutics during the second quarter valued at approximately $28,000.  Quarry LP grew its stake in shares of  Viking Therapeutics by 1,621.4% during the first quarter. Quarry LP now owns 1,205 shares of the biotechnology company's stock valued at $29,000 after buying an additional 1,135 shares during the last quarter.  Elevation Point Wealth Partners LLC bought a new position in shares of  Viking Therapeutics during the second quarter valued at approximately $29,000.  Finally, Parallel Advisors LLC lifted its stake in shares of  Viking Therapeutics by 33.4% during the 2nd quarter. Parallel Advisors LLC now owns 1,818 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 455 shares during the last quarter. Institutional investors own  76.03% of the company's stock. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Several research firms recently commented on VKTX. B. Riley raised shares of Viking Therapeutics to a &#34;strong-buy&#34; rating in a research note on Thursday, October 23rd. Cantor Fitzgerald  set a $105.00 price objective on Viking Therapeutics in a report on Thursday, October 23rd. BTIG Research  reiterated a &#34;buy&#34; rating and set a $125.00 target price on shares of Viking Therapeutics in a report on Monday, September 22nd. Morgan Stanley boosted their price target on shares of Viking Therapeutics from $98.00 to $102.00 and gave the company an &#34;overweight&#34; rating in a report on Thursday, October 23rd. Finally, Canaccord Genuity Group upped their price target on shares of Viking Therapeutics from $106.00 to $107.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, November 12th. Three research analysts have rated the stock with a Strong Buy rating, nine have issued  a Buy rating, three have issued  a Hold rating and one  has issued  a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $87.14.</p><ul><li>Biotech Breakouts: 3 Stocks With Massive Upside Potential</li></ul><p><b>View Our Latest Analysis on VKTX</b></p><h2>Viking Therapeutics Stock Performance</h2><p>Shares of VKTX stock opened at $35.19 on Monday. Viking Therapeutics, Inc. has a fifty-two week low of $18.92 and a fifty-two week high of $45.00. The firm has a market capitalization of $3.98 billion, a price-to-earnings ratio of -16.60 and a beta of 0.65. The stock's 50-day simple moving average is $36.02 and its 200-day simple moving average is $31.71. </p><ul><li>3 Biotech Stocks to Watch: Iovance, Neurocrine &amp; Viking</li></ul><p>Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last released its earnings results on Wednesday, October 22nd. The biotechnology company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.14). During the same period in the prior year, the firm earned ($0.22) EPS. The company's quarterly revenue was up .0% on a year-over-year basis.  As a group, equities analysts forecast that  Viking Therapeutics, Inc. will post -1.56 earnings per share for the current year. </p><h2>Insider Transactions at Viking Therapeutics</h2><p>In other news, COO Marianna Mancini sold 6,185 shares of the firm's stock in a transaction dated Tuesday, October 28th. The stock was sold at an average price of $35.00, for a total value of $216,475.00. Following the completion of the transaction, the chief operating officer directly owned 382,467 shares in the company, valued at $13,386,345. This trade represents a 1.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Brian Lian sold 38,989 shares of the company's stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $35.01, for a total value of $1,365,004.89. Following the completion of the sale, the chief executive officer owned 2,419,109 shares in the company, valued at approximately $84,693,006.09. This represents a 1.59% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 111,359 shares of company stock valued at $3,932,155 in the last quarter. Insiders own  4.10% of the company's stock. </p><h2>About Viking Therapeutics</h2> (Free Report)<p>Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company's pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.  </p><p>The company's lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Viking Therapeutics</li><li>End of America update</li><li>They Laughed at $30. They Won’t Laugh at $70.</li><li>I Shouldn't Be Sending You This</li><li>How Long Will $1M Last in Retirement?</li><li>Bitcoin is down but your income is about to explode</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Viking Therapeutics Right Now?</h2><p>Before you consider Viking Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.</p><p>While Viking Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

VKTX

<p>U.S. Capital Wealth Advisors LLC increased its stake in Viking Therapeutics, Inc. by 48.2% in Q3, owning 94,165 shares worth $2.475 million. Several other hedge funds also adjusted their positions. Analysts have given Viking Therapeutics a consensus rating of 'Moderate Buy' with a price target of $87.14. The stock opened at $35.19, with a 52-week range of $18.92 to $45.00. Recent earnings missed estimates, reporting a loss of $0.81 per share.</p>

U.S. Capital Wealth Advisors LLC Buys 30,619 Shares of Viking Therapeutics, Inc. $VKTX